share_log

RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target

Benzinga ·  Jun 21 22:24

RBC Capital analyst Leonid Timashev reiterates Legend Biotech (NASDAQ:LEGN) with a Outperform and maintains $86 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment